Predictive value of circulating osteonectin in patients with ischemic symptomatic chronic heart failure

Abstract

BackgroundOsteonectin (OSN) plays a pivotal role in cardiac remodeling, but predictive value for OSN in ischemic chronic heart failure (CHF) has not been defined. The aim of the study was to evaluate the prognostic value of OSN for cumulative survival and hospitalization among patients with ischemic-induced CHF.MethodsA total of 154 patients with ischemic symptomatic moderate-to-severe CHF were enrolled in the study at discharge from the hospital. Observation period was up to 3 years (156 weeks). Blood samples for biomarkers measurements were collected at baseline prior to study entry. ELISA methods for measurements of circulating level of OSN were used.ResultsDuring a median follow-up of 2.18 years, 21 participants died and 106 subjects were re-admitted. Medians of circulating levels of OSN in survival and died patient cohorts were 670.96 ng/mL (95% confidence interval [CI] = 636.53–705.35 ng/mL) and 907.84 ng/mL (95% CI = 878.02–937.60 ng/mL). Receiver operation characteristic curve analysis has shown that cut off point of OSN concentration for cumulative survival function was 845.15 ng/mL. It has been found a significant divergence of Kaplan–Meier survival curves in patients with high (>845.15 ng/mL) and low (<845.15 ng/mL) concentrations of OSN. Circulating OSN independently predicted all-cause mortality (odds ratio [OR] = 1.23; 95% CI = 1.10–1.36; p < 0.001), CHF-related death (OR = 1.46; 95% CI = 1.22–1.80; p < 0.001), and also CHF-related re-admission (OR = 1.92; 95% CI = 1.77–2.45; p < 0.001) within 3 years of observation period.ConclusionIncreased circulating secreted protein acidic and rich in cysteine family member OSN associates with increased 3-year CHF-related death, all-cause mortality, and risk for recurrent hospitalization due to CHF.

Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes

“…Decreased serum levels of BDNF were significantly associated with adverse outcomes in HF patients [ 124 , 125 ]. There is a large body of evidence regarding the fact that elevated levels of some SPARC proteins, such as osteonectin and osteopontin, have demonstrated a strong association with poor long-term HF-related outcomes including death, and a risk for recurrent hospitalization due to HF among patients with normal body mass, overweight, and obesity [ 201 , 202 ]. However, there was no finding that osteonectin predicted cardiac cachexia and poor clinical events in patients with HF-related myopathy.…”

Up-to-date clinical approaches of biomarkers’ use in heart failure

“…Indeed, in the PEACE trial levels of OPN were independently associated with the composite CV outcomes and incident HFpEF hospitalization (Abdalrhim et al, 2016). Finally, OSN, OPN and OPG have exhibited the predictive value to mortality rate in HFpEF regardless of its etiology, while there was no axillary discriminative effect in entire predictive score when these biomarkers were added to the NPs, hs-CRP, galectin-3 and sST2 (Berezin and Kremzer, 2015).…”

The Role of Matrix Proteins in Cardiac Pathology

“…The clinical implications of this remain unclear. SPARC levels are increased in patients with coronary artery disease [105,106] and predict adverse cardiovascular outcomes in moderate to severe heart failure [107] but have not proved useful in distinguishing patients with acute MI [108,109].…”

“…[ [105][106][107][108][109] Tenascin C (TN-C) Serum TN-C levels are increased in patients with coronary artery disease (n = 60) compared to controls (n = 20). In patients with ACS, TN-C levels are significantly higher in patients with ruptured plaque (n = 23) compared to those with non-ruptured plaques (n = 29).…”